Inclusion of the FOLFIRINOX regimen in the treatment algorithm for metastatic pancreatic cancer - First experience

Abstract

Pancreatic cancer represents TILDE OPERATOR+D912% of all cancers (6% of all deaths from cancer). This type of cancer has a strong tendency for local invasion and distant metastases.

In patients with advanced pancreatic cancer with a good performance status (0-1) FOLFIRINOX may significantly increase the time to progression and overall survival with a good quality of life.

Keywords

• Efficiency
• FOLFIRINOX
• pancreatic cancer
• toxicity